210 related articles for article (PubMed ID: 23129577)
1. Inhibition of mTOR suppresses UVB-induced keratinocyte proliferation and survival.
Carr TD; DiGiovanni J; Lynch CJ; Shantz LM
Cancer Prev Res (Phila); 2012 Dec; 5(12):1394-404. PubMed ID: 23129577
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of mTOR by apigenin in UVB-irradiated keratinocytes: A new implication of skin cancer prevention.
Bridgeman BB; Wang P; Ye B; Pelling JC; Volpert OV; Tong X
Cell Signal; 2016 May; 28(5):460-468. PubMed ID: 26876613
[TBL] [Abstract][Full Text] [Related]
3. Photopreventive Effect and Mechanism of AZD4547 and Curcumin C3 Complex on UVB-Induced Epidermal Hyperplasia.
Khandelwal AR; Rong X; Moore-Medlin T; Ekshyyan O; Abreo F; Gu X; Nathan CA
Cancer Prev Res (Phila); 2016 Apr; 9(4):296-304. PubMed ID: 26862088
[TBL] [Abstract][Full Text] [Related]
4. Targeting mTORC1/2 with OSI-027 inhibits proliferation and migration of keloid keratinocytes.
Chen J; Liu K; Liu Y; Wang X; Zhang Z
Exp Dermatol; 2019 Mar; 28(3):270-275. PubMed ID: 30650200
[TBL] [Abstract][Full Text] [Related]
5. Negative regulation of the FOXO3a transcription factor by mTORC2 induces a pro-survival response following exposure to ultraviolet-B irradiation.
Feehan RP; Shantz LM
Cell Signal; 2016 Aug; 28(8):798-809. PubMed ID: 27058291
[TBL] [Abstract][Full Text] [Related]
6. DNA-dependent protein kinase catalytic subunit (DNA-PKcs)-SIN1 association mediates ultraviolet B (UVB)-induced Akt Ser-473 phosphorylation and skin cell survival.
Tu Y; Ji C; Yang B; Yang Z; Gu H; Lu CC; Wang R; Su ZL; Chen B; Sun WL; Xia JP; Bi ZG; He L
Mol Cancer; 2013 Dec; 12(1):172. PubMed ID: 24365180
[TBL] [Abstract][Full Text] [Related]
7. PRR5, a novel component of mTOR complex 2, regulates platelet-derived growth factor receptor beta expression and signaling.
Woo SY; Kim DH; Jun CB; Kim YM; Haar EV; Lee SI; Hegg JW; Bandhakavi S; Griffin TJ; Kim DH
J Biol Chem; 2007 Aug; 282(35):25604-12. PubMed ID: 17599906
[TBL] [Abstract][Full Text] [Related]
8. Impact of mTORC1 inhibition on keratinocyte proliferation during skin tumor promotion in wild-type and BK5.AktWT mice.
Rho O; Kiguchi K; Jiang G; DiGiovanni J
Mol Carcinog; 2014 Nov; 53(11):871-82. PubMed ID: 24114993
[TBL] [Abstract][Full Text] [Related]
9. Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin.
Toschi A; Lee E; Xu L; Garcia A; Gadir N; Foster DA
Mol Cell Biol; 2009 Mar; 29(6):1411-20. PubMed ID: 19114562
[TBL] [Abstract][Full Text] [Related]
10. Targeted inhibition of mammalian target of rapamycin signaling inhibits tumorigenesis of colorectal cancer.
Gulhati P; Cai Q; Li J; Liu J; Rychahou PG; Qiu S; Lee EY; Silva SR; Bowen KA; Gao T; Evers BM
Clin Cancer Res; 2009 Dec; 15(23):7207-16. PubMed ID: 19934294
[TBL] [Abstract][Full Text] [Related]
11. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia-induced endothelial proliferation requires both mTORC1 and mTORC2.
Li W; Petrimpol M; Molle KD; Hall MN; Battegay EJ; Humar R
Circ Res; 2007 Jan; 100(1):79-87. PubMed ID: 17110594
[TBL] [Abstract][Full Text] [Related]
13. Conditional disruption of rictor demonstrates a direct requirement for mTORC2 in skin tumor development and continued growth of established tumors.
Carr TD; Feehan RP; Hall MN; Rüegg MA; Shantz LM
Carcinogenesis; 2015 Apr; 36(4):487-97. PubMed ID: 25740823
[TBL] [Abstract][Full Text] [Related]
14. Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR).
García-Martínez JM; Moran J; Clarke RG; Gray A; Cosulich SC; Chresta CM; Alessi DR
Biochem J; 2009 Jun; 421(1):29-42. PubMed ID: 19402821
[TBL] [Abstract][Full Text] [Related]
15. mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling.
Julien LA; Carriere A; Moreau J; Roux PP
Mol Cell Biol; 2010 Feb; 30(4):908-21. PubMed ID: 19995915
[TBL] [Abstract][Full Text] [Related]
16. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2.
Feldman ME; Apsel B; Uotila A; Loewith R; Knight ZA; Ruggero D; Shokat KM
PLoS Biol; 2009 Feb; 7(2):e38. PubMed ID: 19209957
[TBL] [Abstract][Full Text] [Related]
17. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1).
García-Martínez JM; Alessi DR
Biochem J; 2008 Dec; 416(3):375-85. PubMed ID: 18925875
[TBL] [Abstract][Full Text] [Related]
18. Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility.
Gulati N; Karsy M; Albert L; Murali R; Jhanwar-Uniyal M
Int J Oncol; 2009 Oct; 35(4):731-40. PubMed ID: 19724909
[TBL] [Abstract][Full Text] [Related]
19. Impact on Autophagy and Ultraviolet B Induced Responses of Treatment with the MTOR Inhibitors Rapamycin, Everolimus, Torin 1, and pp242 in Human Keratinocytes.
Xu S; Li L; Li M; Zhang M; Ju M; Chen X; Gu H
Oxid Med Cell Longev; 2017; 2017():5930639. PubMed ID: 28400912
[TBL] [Abstract][Full Text] [Related]
20. Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival.
Wang Y; Mikhailova M; Bose S; Pan CX; deVere White RW; Ghosh PM
Oncogene; 2008 Nov; 27(56):7106-17. PubMed ID: 18776922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]